DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform

DataMEDS AI (NASDAQ: MEDS) signed an exclusive license, revenue-sharing and marketing agreement giving it U.S. direct-to-consumer rights to REBOOT Health AI's care management platform. The licensed IP covers six patents and six pending applications for data-driven goal and outcome optimization, which DataMEDS will integrate into its Health Lives Here app for GLP-1 patients on a subscription model, starting with pilots before commercial launch.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.